Phase II Study To Evaluate The Safety and Efficacy of Hemoglobin Raffimer in Patients Undergoing First Time CABG Surgery
NCT ID: NCT00038454
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
SUSPENDED
PHASE2/PHASE3
180 participants
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hemolink (hemoglobin raffimer IV solution)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written Informed Consent.
* Age 18 through 80 years, inclusive.
* Scheduled for primary CABG surgery with CPB and are candidates for IAD.
* Post-induction hemoglobin, which will allow collection of 0-1200 mL inclusive of IAD blood to achieve a target hemoglobin of 7.5 g/dL at 15 minutes on-CPB.
* For women of childbearing potential only, able to use and using a highly-effective contraceptive method from the time of study screening through week 4 - 8 post CABG surgery (follow-up visit).
Note: International Conference on Harmonization (ICH) guidelines define a highly-effective contraceptive method as one with a failure rate of less than one percent when used consistently and correctly
Exclusion Criteria
* Previous treatment with Hemolink(tm) or any other hemoglobin-based oxygen carrier.
* Participation in any clinical trial of an investigational drug, device, or medical procedure within the two months prior to enrollment, or concurrent with participation in this study.
* History of stroke with residual paralysis or of transient ischemic attacks within 6 months prior to surgery.
* Congenital coagulation disorder or treatment with Coumadin within seven days prior to surgery.
* Alcohol or drug use within the 12 months prior to enrollment, which the investigator considers abusive.
* Planned simultaneous surgery (e.g., valve repair or carotid endarterectomy).
* Emergency CABG.
* Previous surgery using sternotomy.
* Current pregnancy or nursing.
* Chronic pancreatitis with or without pancreatic insufficiency.
Any subject who is medically cleared for both the surgical procedure and the intraoperative autologous donation will be eligible for enrollment in the study.
Medical clearance requires the following:
* No current congestive heart failure, New York Heart Association class IV.
* Most recent (within 1 year of surgery) ejection fraction must not be less than or equal to 25 percent, or left ventricular function of grade 4.
* No current uncontrolled hypertension.
* No current severe pulmonary disease which will render the subject at high risk of requiring prolonged post-operative ventilation.
* No serum creatinine \> 2.0 mg/dL (177 umol/L).
* No known AST and ALT and bilirubin \> 3 times the upper limit of normal.
* No uncontrolled angina within 24 hours prior to surgery despite maximal medical treatment, and/or presence of an intraaortic balloon pump preoperatively.
* No history of transmural myocardial infarction within the five days prior to the scheduled CABG surgery.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hemosol
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kaiser Permanente Medical Center - San Francisco-Division of Cardiovascular Anesthesia
San Francisco, California, United States
Stanford University Medical Center: Department of Anesthesiology
Stanford, California, United States
Clinical Research Center
Sarasota, Florida, United States
Heart and Vascular Care
Des Moines, Iowa, United States
Henry Ford Hospital
Detroit, Michigan, United States
Washington University
St Louis, Missouri, United States
Englewood Hospital
Englewood, New Jersey, United States
Robert Wood Johnson Hospital
New Brunswick, New Jersey, United States
Mount Sinai Medical Center
New York, New York, United States
University of North Carolina: Department of Anesthesiology
Chapel Hill, North Carolina, United States
Duke University Medical Center
Durham, North Carolina, United States
The Ohio State University Department of Anesthesiology
Columbus, Ohio, United States
Veterans Affairs Medical Center
Portland, Oregon, United States
Legacy Research
Portland, Oregon, United States
UPMC Health System
Pittsburgh, Pennsylvania, United States
Cardiovascular Anesthesia Research:Texas Heart Institute
Houston, Texas, United States
Inova Fairfax Hospital
Falls Church, Virginia, United States
McGuire VA Medical Center
Richmond, Virginia, United States
Medical College of Virginia: Department of Anesthesiology
Richmond, Virginia, United States
Foothills Medical Centre
Calgary, Alberta, Canada
St. Paul's Hospital/ Vancouver General Hospital
Vancouver, British Columbia, Canada
Kingston General Hospital
Kingston, Ontario, Canada
St. Michael's Hospital
Toronto, Ontario, Canada
The Toronto Hospital - General Division
Toronto, Ontario, Canada
Institut de Cardiologie de Montreal
Montreal, Quebec, Canada
Hopital Laval
Ste Foy, Quebec, Canada
St. Thomas Hospital: Department of Anesthesia
London, England, United Kingdom
Southampton General Hospital
Southampton, England, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Jahr JS, Lurie F, Driessen B, Davis JA, Gosselin R, Gunther RA. The HemoCue, a point of care B-hemoglobin photometer, measures hemoglobin concentrations accurately when mixed in vitro with canine plasma and three hemoglobin-based oxygen carriers (HBOC). Can J Anaesth. 2002 Mar;49(3):243-8. doi: 10.1007/BF03020522.
Kingma JG Jr, Sandhu R, Hamelin ND, Gendron D, Trudel Y, Bosa M, Stewart R, Fargey MB, Biro GP. The effects of hemodilution with Hemolink upon hemodynamics and blood flow distribution in anesthetized dogs. Artif Cells Blood Substit Immobil Biotechnol. 2001 Nov;29(6):465-81. doi: 10.1081/bio-100108551.
Topfer LA, Hailey D. Oxygen carriers ("blood substitutes"). Issues Emerg Health Technol. 2001 Jul;(21):1-6.
Scatena R, Giardina B. O-raffinose-polymerised haemoglobin. A biochemical and pharmacological profile of an oxygen carrier. Expert Opin Biol Ther. 2001 Jan;1(1):121-7. doi: 10.1517/14712598.1.1.121.
Cheng DC. Safety and efficacy of o-raffinose cross-linked human hemoglobin (Hemolink) in cardiac surgery. Can J Anaesth. 2001 Apr;48(4 Suppl):S41-8.
Caron A, Malfatti E, Aguejouf O, Faivre-Fiorina B, Menu P. Vasoconstrictive response of rat mesenteric arterioles following infusion of cross-linked, polymerized, and conjugated hemoglobin solutions. Artif Cells Blood Substit Immobil Biotechnol. 2001 Jan;29(1):19-30. doi: 10.1081/bio-100001253.
Toussaint M, Latger-Cannard V, Caron A, Lecompte T, Stoltz JF, Vigneron C, Menu P. Effects of three Hb-based oxygen-carrying solutions on neutrophil activation in vitro: quantitative measurement of the expression of adherence receptors. Transfusion. 2001 Feb;41(2):226-31. doi: 10.1046/j.1537-2995.2001.41020226.x.
Carmichael FJ, Ali AC, Campbell JA, Langlois SF, Biro GP, Willan AR, Pierce CH, Greenburg AG. A phase I study of oxidized raffinose cross-linked human hemoglobin. Crit Care Med. 2000 Jul;28(7):2283-92. doi: 10.1097/00003246-200007000-00017.
Cohn SM. Blood substitutes in surgery. Surgery. 2000 Jun;127(6):599-602. doi: 10.1067/msy.2000.106462. No abstract available.
Ning J, Wong LT, Christoff B, Carmichael FJ, Biro GP. Haemodynamic response following a 10% topload infusion of HemolinkTM in conscious, anaesthetized and treated spontaneously hypertensive rats. Transfus Med. 2000 Mar;10(1):13-22. doi: 10.1046/j.1365-3148.2000.00225.x.
Lieberthal W, Fuhro R, Andry C, Valeri CR. Effects of hemoglobin-based oxygen-carrying solutions in anesthetized rats with acute ischemic renal failure. J Lab Clin Med. 2000 Jan;135(1):73-81. doi: 10.1016/s0022-2143(00)70023-0.
Xue S, Paterson W, Valdez D, Miller D, Christoff B, Wong LT, Diamant NE. Effect of an o-raffinose cross-linked haemoglobin product on oesophageal and lower oesophageal sphincter motor function. Neurogastroenterol Motil. 1999 Dec;11(6):421-30. doi: 10.1046/j.1365-2982.1999.00171.x.
Freilich D, Branda R, Hacker M, Leach L, Barry B, Ferris S, Hebert J. Decreased lactic acidosis and anemia after transfusion of o-raffinose cross-linked and polymerized hemoglobin in severe murine malaria. Am J Trop Med Hyg. 1999 Feb;60(2):322-8. doi: 10.4269/ajtmh.1999.60.322.
Lieberthal W, Fuhro R, Freedman JE, Toolan G, Loscalzo J, Valeri CR. O-raffinose cross-linking markedly reduces systemic and renal vasoconstrictor effects of unmodified human hemoglobin. J Pharmacol Exp Ther. 1999 Mar;288(3):1278-87.
Glaser V. Fake blood market gets hemoglobin transfusion from reticulocytes. Nat Biotechnol. 1998 Aug;16(8):709. doi: 10.1038/nbt0898-709. No abstract available.
Macdonald RL, Zhang J, Weir B, Marton LS, Wollman R. Adenosine triphosphate causes vasospasm of the rat femoral artery. Neurosurgery. 1998 Apr;42(4):825-32; discussion 832-3. doi: 10.1097/00006123-199804000-00082.
Balion CM, Champagne PA, Ali AC. Evaluation of HemogloBind for removal of o-raffinose cross-linked hemoglobin (Hemolink) from serum. Clin Chem. 1997 Sep;43(9):1796-7. No abstract available.
Ali AC, Mihas CC, Campbell JA. Interferences of o-raffinose cross-linked hemoglobin in three methods for serum creatinine. Clin Chem. 1997 Sep;43(9):1738-43.
Kerger H, Tsai AG, Saltzman DJ, Winslow RM, Intaglietta M. Fluid resuscitation with O2 vs. non-O2 carriers after 2 h of hemorrhagic shock in conscious hamsters. Am J Physiol. 1997 Jan;272(1 Pt 2):H525-37. doi: 10.1152/ajpheart.1997.272.1.H525.
Baines AD, Christoff B, Wicks D, Wiffen D, Pliura D. Cross-linked hemoglobin increases fractional reabsorption and GFR in hypoxic isolated perfused rat kidneys. Am J Physiol. 1995 Nov;269(5 Pt 2):F628-36. doi: 10.1152/ajprenal.1995.269.5.F628.
Wong LT, Er SS, Ning J, Christoff B, Carmichael FJ. Hemolink-induced effects on intestinal motor function and attenuation of these effects by selected agents. Artif Cells Blood Substit Immobil Biotechnol. 1998 Nov;26(5-6):529-48. doi: 10.3109/10731199809117473.
Ali AC, Campbell JA. Interference of o-raffinose cross-linked hemoglobin with routine Hitachi 717 assays. Clin Chem. 1997 Sep;43(9):1794-6. No abstract available.
Arnoldo BD, Minei JP. Potential of hemoglobin-based oxygen carriers in trauma patients. Curr Opin Crit Care. 2001 Dec;7(6):431-6. doi: 10.1097/00075198-200112000-00010.
Caron A, Menu P, Faivre-Fiorina B, Labrude P, Alayash AI, Vigneron C. Cardiovascular and hemorheological effects of three modified human hemoglobin solutions in hemodiluted rabbits. J Appl Physiol (1985). 1999 Feb;86(2):541-8. doi: 10.1152/jappl.1999.86.2.541.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HLK-213
Identifier Type: -
Identifier Source: org_study_id